New Life Sciences Strategy to help grow sector to £8bn by 2025

Life Sciences Scotland Industry Leadership Group says it’s an exciting time for life sciences businesses in Scotland 

The new 2017 Life Sciences Strategy for Scotland is set to be launched tonight (Thursday, 2 February) – outlining ambitions of growing industrial turnover of the life sciences sector to £8 billion by 2025.
Developed by the Life Sciences Scotland Industry Leadership Group and other contributors representing the various key life sciences subsectors, the new vision, which will be unveiled at Scotland’s Life Sciences Dinner and Awards, will harness the outstanding achievements of the sector of the last few years.
According to Scottish Enterprise, the life sciences industry has achieved impressive expansion since 2010. The latest sector figures (2014 data) show that the sector employs more than 37,000 people across some 700 organisations; company turnover is in excess of £4.2 billion and gross value added (GVA) around £2 billion. Between 2010 and 2014 company turnover increased by 29%, gross value added by 24% and total employment in companies by 13%.
It claims Scotland is already a leading global life sciences cluster and in the past few years has seen many positive developments, with a number of international companies looking to expand their presence here.
Approximately £300 million has been invested over the past three years across the sector, by companies including Capsugel, GSK, Johnson Matthey, Piramal Healthcare, Quotient and ThermoFisher Scientific.
Dave Tudor, VP of Primary Supply Chain at GSK, industry chair of Life Sciences Scotland, the Life Sciences Scotland Industry Leadership Group (ILG), said: “This is an exciting time for life sciences businesses in Scotland. I am delighted with the shape of our refreshed strategy and the strategic themes that have been identified. We now need focus and alignment from across the sector as we create the Working Groups that will plan and coordinate the delivery of this strategy. I look forward to working with everyone to ensure success in the future.” 
The Life Sciences Scotland ILG is co-chaired by Paul Wheelhouse, MSP, Minister for Business, Innovation and Energy, supported by Ms Aileen Campbell, MSP, Minister for Public Health and Sport.
Minister for Business, Innovation and Energy Paul Wheelhouse said: “These statistics published today show the value of the Life Sciences industry to Scotland, providing employment for over 37,000 people, with company turnover in excess of £4.2 billion – up 29 per cent between 2010 and 2014.
“I welcome the publication of this ambitious industry-led strategy for the Life Sciences, which support the aim to increase annual turnover by a further 90 per cent to £8 billion by 2025.
“The sector has delivered a strong performance in recent years and is a key driver of innovation in Scotland with a particularly strong employment impact in and around Scotland’s cities, and that is why it is vital we continue to provide a supportive environment for business growth and fulfil our ambitions to be a world-leading entrepreneurial and innovative nation.
“EU nationals living in Scotland and working in the Life Sciences sector greatly enrich our culture, strengthen our society and boost our economy and the Scottish Government recognises the very welcome contribution they make to our country. That is why we are exploring all possible avenues for Scotland to retain the benefits of EU membership‎.”
Julia Brown, senior director of Healthcare, Life and Chemical Sciences at Scottish Enterprise, said: “I am delighted to see the impressive expansion of the sector over the past few years, which is the result of concerted collaborative efforts from the Scottish life sciences community.  Scottish Enterprise will continue to work with the Life Science Scotland ILG, industry and all life sciences sector stakeholders to keep the momentum and achieve the ambitious growth targets outlined in this strategy.”
In the last two years, Scotland has attracted significant international investment through acquisition. Nikon bought medical technology company Optos, which will become the cornerstone of its new medical group. Biopta was acquired by Reprocell, a Japanese stem cell specialist. Medical technology giant Medtronic purchased anaesthesia specialist Aircraft Medical; Merck bought IOmet Pharma; French specialist Sartorius Stedim acquired BioOutsource, and Icelandic prosthetics specialist Ossϋr acquired Touch Bionics.
Also, a number of new companies have located in Scotland, including Cellexus, Dexcom and Janssen Pharmaceuticals, HCi Viocare, Orion Health, Sinovet and Greengage, proving just how attractive Scotland is as a place to invest – and a great location to build and grow a life sciences business.
Scotland has also enhanced its investment offering in recent years, leading to Epidarex establishing a £50 million venture fund supported by a diverse range of investors, including Eli Lilly’s first venture fund investment within the UK.
With 30%of its portfolio in life sciences, the Scottish Investment Bank (SIB) is one of the most active investor in life sciences in the UK. The Scottish Investment Bank has invested £39 million in the sector over the last 5 years, leveraging £98.6 million in private funds which has been a great stimulus to the sector.
This week the Series A investment announcement from TC BioPharm to progress lead product ImmuniCell® to phase III clinical trial in patients with skin, lung and kidney cancer further demonstrates the attractiveness of Scottish life sciences sector.
Sponsored by
Hannah Hamilton, who is a former Fife College student, is a reporter and assistant content editor for Scotland B2B, specialising in B2B news and features. She can be contacted via